

03 May 2022

## **Subject:**

**Q1. How many GP practices are covered by your Health and Social Care Trust?**

**Q2. For the financial years 2019/2020 and 2021/22 how much did you spend on:**

**Osteoporosis medication with:**

**i) Oral bisphosphonates (alendronate, risedronate, ibandronate)**

**a. 2019/2020**

**b. 2020/2021**

**ii) Denosumab**

**a. 2019/2020**

**b. 2020/2021**

**DXA scans. Please provide:**

**i) budget/spend for DXA**

**a. 2019/2020**

**b. 2020/2021**

**ii) n. scans this provided**

**a. 2019/2020**

**b. 2020/2021**

**iii) n. DXA VFA (vertebral fracture assessment) scans commissioned**

**a. 2019/2020**

**b. 2020/2021**

**Q3. What proportion of GP practices have a systematic process in place (e.g., regular data search) for identifying people who require a fracture risk assessment?**

**Q4. What proportion of GP practices have osteoporosis identification/management tools embedded into their electronic patient management systems?**

**a) FRAX**

**b) QFracture**

**c) Other (please state)**

**Q5. For financial years 2019/20 and 2021/22.**

**a) What proportion of patients across your CCG aged 50 and over had a fracture risk assessment using FRAX or QFracture in line with NICE / NOGG recommendations?**

**03 May 2022**

- i. 2019/2020
- ii. 2020/2021
- b) What proportion of these were referred for a DXA scan?
  - i. 2019/2020
  - ii. 2020/2021

**Q6. What proportion of practices have an identified clinician or other healthcare professional with special interest in osteoporosis?**

**Q7. What proportion of GP practices have access to a community pharmacist (CP)?**

**And: what proportion of these CPs have a designated role in identifying/managing osteoporosis? What proportion of these CPs routinely perform osteoporosis medication reviews?**

**Q8. What proportion of GP practices have access to a First Contact Practitioner (FCP)? What proportion of these FCPs have a designated role in identifying/managing OP?**

**Q9. What proportion of patients being treated in primary care with osteoporosis medications have had a review of their medication within 12 months of treatment initiation?**

**Q10. What proportion of patients being treated in primary care with oral bisphosphonate therapy have had their treatment reviewed at 5 years of treatment?**

## **Answer**

This FOI relates to GP practice provision for Osteoporosis treatment in primary care. BHSC provide a secondary care service so this request is not relevant to us.

If you could redirect your request to the Department of Health, who have responsibility for GP practice provision.